LY-3962681

N/A

Report date: 2024/08/23 20:00:42

Base Information

Drug NameLY-3962681
Drug Alias NameLY3962681LY-3962681
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionGene transference
TargetsUpdating
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPrevail Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesPrevail Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A